奥戈伏单抗

奥戈伏单抗
单克隆抗体
种类完整抗体
目標CA125
臨床資料
商品名（英语：Drug nomenclature）OvaRex
ATC碼
  • 未分配
识别信息
CAS号213327-37-8  checkY
ChemSpider
  • none
UNII
KEGG
化学信息
摩尔质量ca. 150 kg/mol

奥戈伏单抗（INN：Oregovomab；商品名OvaRex销售）是一种小鼠单克隆抗体，它与抗原CA125（一种碳水化合物抗原）结合。它被设计用于治疗卵巢癌。[1][2]

该药物由AltaRex公司开发。[3]

参考资料

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Oregovomab （页面存档备份，存于互联网档案馆）, American Medical Association.
  2. ^ Pietragalla, Antonella; Duranti, Simona; Daniele, Gennaro; Nero, Camilla; Ciccarone, Francesca; Lorusso, Domenica; Fagotti, Anna; Scambia, Giovanni. Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. Expert Opinion on Investigational Drugs. 2021-02, 30 (2). ISSN 1744-7658. PMID 33423551. doi:10.1080/13543784.2021.1868436. 
  3. ^ Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13. Drugs in R&D. 2006, 7 (6) [2024-03-04]. ISSN 1174-5886. PMID 17073521. doi:10.2165/00126839-200607060-00007. （原始内容存档于2024-06-04）.